Literature DB >> 9564011

Tolerability of alendronate. Comparison group taking placebo should have been included.

M Kirby.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9564011      PMCID： PMC1113090          DOI： 10.1136/bmj.316.7141.1389a

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Prescription-event monitoring (PEM) in 1996-a method of non-interventional observational cohort pharmacovigilance.

Authors:  R D Mann; L V Wilton; G L Pearce; F J Mackay; N R Dunn
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-10       Impact factor: 2.890

2.  Incidence of gastrointestinal side effects due to alendronate is high in clinical practice.

Authors:  R Kelly; H Taggart
Journal:  BMJ       Date:  1997-11-08

3.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

4.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 5.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245
  5 in total
  1 in total

1.  Pharmacovigilance study of alendronate in England.

Authors:  Pipasha N Biswas; Lynda V Wilton; Saad A W Shakir
Journal:  Osteoporos Int       Date:  2003-04-23       Impact factor: 4.507
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.